TM6SF2 rs58542926 Polymorphism is not Associated With Risk of Steatosis or Fibrosis in Chilean Patients With Chronic Hepatitis C
Author
dc.contributor.author
Urzúa Manchego, Álvaro
Author
dc.contributor.author
Mezzano, Gabriel
Author
dc.contributor.author
Brahm Barril, Javier
Author
dc.contributor.author
Poniachik Teller, Jaime
Author
dc.contributor.author
Miranda, Julio
Author
dc.contributor.author
Carreno, Laura
Author
dc.contributor.author
Venegas Santos, Mauricio
Admission date
dc.date.accessioned
2017-10-19T18:17:30Z
Available date
dc.date.available
2017-10-19T18:17:30Z
Publication date
dc.date.issued
2017
Cita de ítem
dc.identifier.citation
Hepat Mon. 2017 April; 17(4):e44365.
es_ES
Identifier
dc.identifier.other
10.5812/hepatmon.44365
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/145299
Abstract
dc.description.abstract
Background: The polymorphism rs58542926 C > T (E167K) in the gene of transmembrane 6 superfamily member 2 (TM6SF2) has
been identified as a determinant of hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Only limited data
have been published on this subject in chronic hepatitis C (CHC).
Objectives: This study aimed to evaluate the effect of TM6SF2 rs58542926 polymorphism on the risk of liver steatosis and fibrosis in
Chilean patients with CHC infection.
Methods: A total of 153 biopsied CHC patients were genotyped for TM6SF2 rs58542926 using PCR-RFLP methodology. The risk of
fatty liver was assessed by comparing absence (< 5 %) with presence ( 5 %) of steatosis. The association with fibrosis was evaluated
according to METAVIR score, by comparing patients in stage F0, F1, or F2 with patients in stage F3 or F4.
Results: TM6SF2 rs58542926 genotype CC was found in 138 (90.2%) patients, whereas genotypes CT was found in 15 (9.8 %). No association
was observed between rs58542926 genotype and risk of steatosis (OR 0.62, 95% CI 0.17 - 2.22, P = 0.459) or fibrosis (OR 1.07, 95%
CI 0.29 - 3.87, P = 0.923).
Conclusions: TM6SF2 rs58542926 polymorphism is not associated with the risk of liver steatosis or fibrosis in Chilean patients with
CHC.